|
2016-02-23 |
2016-02-19 |
B
Purchase
|
Flynn James E
Large shareholder
|
11,745
+0.4%
3.99
USD 46,843
|
11,745
+0.4%
|
3.99
|
USD 46,843
|
|
|
2016-02-23 |
2016-02-19 |
B
Purchase
|
Flynn James E
Large shareholder
|
9,228
+0.4%
3.99
USD 36,804
|
9,228
+0.4%
|
3.99
|
USD 36,804
|
|
|
2016-02-16 |
2016-02-12 |
B
Purchase
|
Flynn James E
Large shareholder
|
19,725
+0.7%
3.92
USD 77,381
|
19,725
+0.7%
|
3.92
|
USD 77,381
|
|
|
2016-02-16 |
2016-02-12 |
B
Purchase
|
Flynn James E
Large shareholder
|
15,499
+0.7%
3.92
USD 60,803
|
15,499
+0.7%
|
3.92
|
USD 60,803
|
|
|
2016-02-16 |
2016-02-11 |
B
Purchase
|
Flynn James E
Large shareholder
|
1,157,189
+74.3%
3.76
USD 4,349,642
|
1,157,189
+74.3%
|
3.76
|
USD 4,349,642
|
|
|
2016-02-16 |
2016-02-11 |
B
Purchase
|
Flynn James E
Large shareholder
|
909,221
+74.3%
3.76
USD 3,417,580
|
909,221
+74.3%
|
3.76
|
USD 3,417,580
|
|
|
2016-02-16 |
2016-02-11 |
B
Purchase
|
Flynn James E
Large shareholder
|
1,557,991
+inf%
3.96
USD 6,166,840
|
1,557,991
+inf%
|
3.96
|
USD 6,166,840
|
|
|
2016-02-16 |
2016-02-11 |
B
Purchase
|
Flynn James E
Large shareholder
|
1,224,136
+inf%
3.96
USD 4,845,375
|
1,224,136
+inf%
|
3.96
|
USD 4,845,375
|
|
|
2016-01-22 |
2016-01-20 |
B
Purchase
|
Flynn James E
Large shareholder
|
346,417
+5.5%
4.09
USD 1,418,404
|
346,417
+5.5%
|
4.09
|
USD 1,418,404
|
|
|
2015-11-13 |
2015-11-11 |
S
Sale
|
Freund John Gordon
Non-Executive Director
|
909
-0.2%
6.68
USD 6,074
|
909
-0.2%
|
6.68
|
USD 6,074
|
|
|
2015-07-15 |
2015-07-15 |
PS
Planned sale
|
Barrett Ronald W
Chief Executive Officer
Executive Director
|
12,500
-5.8%
7.20
USD 90,000
|
12,500
-5.8%
|
7.20
|
USD 90,000
|
|
|
2015-05-12 |
2015-05-11 |
B
Purchase
|
WIERENGA WENDALL
Non-Executive Director
|
5,000
+20.8%
5.63
USD 28,169
|
5,000
+20.8%
|
5.63
|
USD 28,169
|
|
|
2014-12-12 |
2014-12-10 |
S
Sale
|
RIEFLIN WILLIAM JL
Non-Executive Director
|
2,500
-10.3%
8.49
USD 21,225
|
2,500
-10.3%
|
8.49
|
USD 21,225
|
|
|
2014-12-12 |
2014-12-10 |
S
Sale
|
RIEFLIN WILLIAM JL
Non-Executive Director
|
5,592
-18.8%
8.49
USD 47,476
|
5,592
-18.8%
|
8.49
|
USD 47,476
|
|
|
2014-12-12 |
2014-12-10 |
S
Sale
|
RIEFLIN WILLIAM JL
Non-Executive Director
|
2,918
-8.9%
8.49
USD 24,774
|
2,918
-8.9%
|
8.49
|
USD 24,774
|
|
|
2014-12-10 |
2014-12-08 |
S
Sale
|
Barrett Ronald W
Chief Executive Officer
Executive Director
|
3,000
-1.8%
8.40
USD 25,200
|
3,000
-1.8%
|
8.40
|
USD 25,200
|
|
|
2014-12-10 |
2014-12-08 |
S
Sale
|
Barrett Ronald W
Chief Executive Officer
Executive Director
|
2,000
-1.2%
8.35
USD 16,700
|
2,000
-1.2%
|
8.35
|
USD 16,700
|
|
|
2014-12-10 |
2014-12-08 |
S
Sale
|
Barrett Ronald W
Chief Executive Officer
Executive Director
|
1,015
-0.6%
8.32
USD 8,445
|
1,015
-0.6%
|
8.32
|
USD 8,445
|
|
|
2014-12-10 |
2014-12-08 |
S
Sale
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Officer
|
9,581
-31.6%
8.35
USD 80,001
|
9,581
-31.6%
|
8.35
|
USD 80,001
|
|
|
2014-12-10 |
2014-12-08 |
S
Sale
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Officer
|
4,585
-18.1%
8.35
USD 38,285
|
4,585
-18.1%
|
8.35
|
USD 38,285
|
|
|
2014-12-10 |
2014-12-08 |
S
Sale
|
Barrett Ronald W
Chief Executive Officer
Executive Director
|
1,000
-0.6%
8.30
USD 8,303
|
1,000
-0.6%
|
8.30
|
USD 8,303
|
|
|
2014-12-08 |
2014-12-05 |
S
Sale
|
Bosko Gianna M
SVP, CLO and Secretary
Officer
|
20,000
-20.6%
8.40
USD 168,000
|
20,000
-20.6%
|
8.40
|
USD 168,000
|
|
|
2014-12-08 |
2014-12-05 |
S
Sale
|
Bosko Gianna M
SVP, CLO and Secretary
Officer
|
21,348
-21.7%
8.45
USD 180,418
|
21,348
-21.7%
|
8.45
|
USD 180,418
|
|
|
2014-12-08 |
2014-12-04 |
S
Sale
|
Bosko Gianna M
SVP, CLO and Secretary
Officer
|
7,399
-8.8%
8.50
USD 62,897
|
7,399
-8.8%
|
8.50
|
USD 62,897
|
|
|
2014-12-08 |
2014-12-04 |
S
Sale
|
Bosko Gianna M
SVP, CLO and Secretary
Officer
|
11,253
-12.7%
8.50
USD 95,658
|
11,253
-12.7%
|
8.50
|
USD 95,658
|
|
|
2014-09-10 |
2014-09-09 |
S
Sale
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Officer
|
5,612
-21.3%
5.26
USD 29,519
|
5,612
-21.3%
|
5.26
|
USD 29,519
|
|
|
2014-06-04 |
2014-06-03 |
B
Purchase
|
Freund John Gordon
Non-Executive Director
|
12,500
+123.4%
3.93
USD 49,164
|
12,500
+123.4%
|
3.93
|
USD 49,164
|
|
|
2014-05-27 |
2014-05-27 |
B
Purchase
|
FRIEDMAN CATHY
Non-Executive Director
|
2,600
+inf%
3.92
USD 10,179
|
2,600
+inf%
|
3.92
|
USD 10,179
|
|
|
2014-05-27 |
2014-05-27 |
B
Purchase
|
WIERENGA WENDALL
Non-Executive Director
|
10,000
+71.4%
3.99
USD 39,900
|
10,000
+71.4%
|
3.99
|
USD 39,900
|
|
|
2014-05-27 |
2014-05-27 |
B
Purchase
|
FENTON DENNIS M
Non-Executive Director
|
3,000
+30.0%
4.02
USD 12,046
|
3,000
+30.0%
|
4.02
|
USD 12,046
|
|
|
2014-05-28 |
2014-05-23 |
B
Purchase
|
Barrett Ronald W
Chief Executive Officer
Executive Director
|
2,600
+1.5%
3.75
USD 9,745
|
2,600
+1.5%
|
3.75
|
USD 9,745
|
|
|
2014-05-27 |
2014-05-23 |
B
Purchase
|
Freund John Gordon
Non-Executive Director
|
9,500
+81.2%
3.72
USD 35,354
|
9,500
+81.2%
|
3.72
|
USD 35,354
|
|
|
2014-05-27 |
2014-05-23 |
B
Purchase
|
MARIO ERNEST
Non-Executive Director
|
30,000
+55.8%
3.73
USD 111,978
|
30,000
+55.8%
|
3.73
|
USD 111,978
|
|
|
2014-05-27 |
2014-05-22 |
B
Purchase
|
Freund John Gordon
Non-Executive Director
|
5,500
+88.7%
3.75
USD 20,623
|
5,500
+88.7%
|
3.75
|
USD 20,623
|
|
|
2014-05-16 |
2014-05-15 |
PS
Planned sale
|
BERNS PAUL L
Non-Executive Director
|
2,500
-33.3%
3.66
USD 9,150
|
2,500
-33.3%
|
3.66
|
USD 9,150
|
|
|
2013-06-17 |
2013-06-14 |
S
Sale
|
BATES GREGORY T
SVP, Regulatory Affairs & QA
Officer
|
7,500
-31.2%
5.35
USD 40,125
|
7,500
-31.2%
|
5.35
|
USD 40,125
|
|
|
2013-05-23 |
2013-05-22 |
B
Purchase
|
MARIO ERNEST
Non-Executive Director
|
20,000
+200.0%
5.49
USD 109,800
|
20,000
+200.0%
|
5.49
|
USD 109,800
|
|
|
2012-08-09 |
2012-08-09 |
B
Purchase
|
MARIO ERNEST
Non-Executive Director
|
10,000
+inf%
8.50
USD 84,983
|
10,000
+inf%
|
8.50
|
USD 84,983
|
|
|
2011-12-16 |
2011-12-16 |
B
Purchase
|
RIEFLIN WILLIAM JL
Non-Executive Director
|
10,000
+3.7%
3.86
USD 38,580
|
10,000
+3.7%
|
3.86
|
USD 38,580
|
|
|
2011-11-22 |
2011-11-21 |
B
Purchase
|
RIEFLIN WILLIAM JL
Non-Executive Director
|
10,000
+3.8%
4.44
USD 44,413
|
10,000
+3.8%
|
4.44
|
USD 44,413
|
|
|
2011-11-09 |
2011-11-07 |
B
Purchase
|
RIEFLIN WILLIAM JL
Non-Executive Director
|
5,000
+2.0%
5.49
USD 27,452
|
5,000
+2.0%
|
5.49
|
USD 27,452
|
|
|
2010-11-12 |
2010-11-12 |
B
Purchase
|
FENTON DENNIS M
Non-Executive Director
|
300
+30.0%
7.86
USD 2,358
|
300
+30.0%
|
7.86
|
USD 2,358
|
|
|
2010-11-12 |
2010-11-12 |
B
Purchase
|
FENTON DENNIS M
Non-Executive Director
|
35
+3.6%
7.87
USD 275
|
35
+3.6%
|
7.87
|
USD 275
|
|
|
2010-11-12 |
2010-11-12 |
B
Purchase
|
FENTON DENNIS M
Non-Executive Director
|
100
+11.6%
7.92
USD 792
|
100
+11.6%
|
7.92
|
USD 792
|
|
|
2010-11-12 |
2010-11-12 |
B
Purchase
|
FENTON DENNIS M
Non-Executive Director
|
100
+13.1%
7.93
USD 793
|
100
+13.1%
|
7.93
|
USD 793
|
|
|
2010-11-12 |
2010-11-12 |
B
Purchase
|
FENTON DENNIS M
Non-Executive Director
|
765
+inf%
7.94
USD 6,071
|
765
+inf%
|
7.94
|
USD 6,071
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
18.47
USD 1,847
|
100
-0.7%
|
18.47
|
USD 1,847
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
18.43
USD 1,843
|
100
-0.7%
|
18.43
|
USD 1,843
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
18.58
USD 1,858
|
100
-0.7%
|
18.58
|
USD 1,858
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
18.61
USD 1,861
|
100
-0.7%
|
18.61
|
USD 1,861
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
18.52
USD 1,852
|
100
-0.7%
|
18.52
|
USD 1,852
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.50
USD 1,850
|
100
-0.6%
|
18.50
|
USD 1,850
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.46
USD 1,846
|
100
-0.6%
|
18.46
|
USD 1,846
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.39
USD 1,839
|
100
-0.6%
|
18.39
|
USD 1,839
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.32
USD 1,832
|
100
-0.6%
|
18.32
|
USD 1,832
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.30
USD 1,830
|
100
-0.6%
|
18.30
|
USD 1,830
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.2%
18.36
USD 3,672
|
200
-1.2%
|
18.36
|
USD 3,672
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.2%
18.49
USD 3,698
|
200
-1.2%
|
18.49
|
USD 3,698
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.57
USD 1,857
|
100
-0.6%
|
18.57
|
USD 1,857
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.2%
18.60
USD 3,720
|
200
-1.2%
|
18.60
|
USD 3,720
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
30
-0.2%
18.79
USD 564
|
30
-0.2%
|
18.79
|
USD 564
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
2
-0.0%
18.80
USD 38
|
2
-0.0%
|
18.80
|
USD 38
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
68
-0.4%
18.81
USD 1,279
|
68
-0.4%
|
18.81
|
USD 1,279
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.68
USD 1,868
|
100
-0.6%
|
18.68
|
USD 1,868
|
|
|
2010-02-04 |
2010-02-01 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.6%
18.72
USD 1,872
|
100
-0.6%
|
18.72
|
USD 1,872
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
19.20
USD 1,920
|
100
-0.7%
|
19.20
|
USD 1,920
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
19.17
USD 1,917
|
100
-0.7%
|
19.17
|
USD 1,917
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
19.52
USD 1,952
|
100
-0.7%
|
19.52
|
USD 1,952
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
19.36
USD 1,936
|
100
-0.7%
|
19.36
|
USD 1,936
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
32
-0.2%
19.26
USD 616
|
32
-0.2%
|
19.26
|
USD 616
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
268
-1.8%
19.25
USD 5,159
|
268
-1.8%
|
19.25
|
USD 5,159
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.4%
19.28
USD 3,856
|
200
-1.4%
|
19.28
|
USD 3,856
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
19.23
USD 1,923
|
100
-0.7%
|
19.23
|
USD 1,923
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.3%
19.22
USD 3,844
|
200
-1.3%
|
19.22
|
USD 3,844
|
|
|
2010-01-06 |
2010-01-04 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.7%
19.27
USD 1,927
|
100
-0.7%
|
19.27
|
USD 1,927
|
|
